argenx

argenx is a biopharmaceutical company that develops immunology solutions through an antibody innovation ecosystem. The company engineers therapeutic antibodies in collaboration with academic partners to treat severe autoimmune diseases. argenx markets efgartigimod (VYVGART and VYVGART Hytrulo) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, and evaluates other product candidates targeting disease pathways where antibodies are pathogenic.